论文部分内容阅读
AIM:To study the therapeutic effect of interferon(IFN)and ribavirin with zinc supplement on patients withchronic hepatitis C viral(HCV)infection.METHODS:A total of 102 patients confirmedhistologically to have chronic HCV infection withgenotype 1b and more than 100 KIU/mL of HCV wererandomly assigned to each arm of the study and eachreceived 10 million units of pegylated interferon(IFN-alpha-2b)daily for 4 wk followed by the same dose everyother day for 20 wk plus ribavirin(600 or 800 mg/ddepending on body weight),with or without polaprezinc(150 mg/d)orally for 24 wk.The primary endpoint wassustained virological response(SVR)defined as negativeHCV-RNA in the serum 6 mo after treatment.RESULTS:There were no differences in the clinicalbackground between the two groups except for morefemales in the dual therapy group than in the othergroup(P<0.05).SVR was observed in 33.3% of thetriple therapy group and 33.3% of the dual therapygroup.The side effects were almost the same in bothgroups except for gastrointestinal symptoms,which wereless in the triple therapy group(P=0.019).CONCLUSION:Considered together,triple therapy ofzinc plus IFN and ribavirin for HCV infection patients withgenotype 1b and high viral load is not better than dualtherapy except for lower incidence of gastrointestinalside effects.
AIM: To study the therapeutic effect of interferon (IFN) and ribavirin with zinc supplement on patients with chronic hepatitis C viral (HCV) infection. DETHODS: A total of 102 patients confirmed to have chronic infection with genotype 1b and more than 100 KIU / mL of HCV were randomly assigned to each arm of the study and eachreceived 10 million units of pegylated interferon (IFN-alpha-2b) daily for 4 weeks followed by the same dose every other day for 20 weeks plus ribavirin (600 or 800 mg / ddepending on body weight with or without polaprezinc (150 mg / d) orally for 24 wk. The primary endpoint wassustained virological response (SVR) defined as negativeHCV-RNA in the serum 6 months after treatment .RESULTS: There were no differences in the clinical background between the two groups except for morefemales in the dual therapy group than in the other group (P <0.05) .SVR was observed in 33.3% of thetriple therapy group and 33.3% of the dual therapygroup.The side effects were almost the same in bothgroupss exce pCL for gastrointestinal symptoms, which were not in the triple therapy group (P = 0.019) .CONCLUSION: Considered together, triple therapy of zinc plus IFN and ribavirin for HCV infection patients with genotype 1b and high viral load is not better than dual therapy except for lower incidence of gastrointestinalside effects.